medigraphic.com

2003, Number 4

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2003; 41 (4)

Hormone Replacement Therapy. Considerations of Findings in 2002

Velasco MV

Language: Spanish
References: 21
Page: 321-328
PDF size: 131.65 Kb.


ABSTRACT

The results of multiple research studies worldwide in the last 30 years concluded that benefits of hormonal replacement therapy during climacteric and postmenopause outweigh the risks of administration. Among others, the main benefits mentioned were prevention of postmenopausal osteoporosis, favorable changes in some parameters of cardiovascular risk, and improvement in cognitive and affective functions observed in patients under treatment. Therefore, results of some recent prospective research studies that tested the oral combination with 0.625 mg of conjugated equine estrogens and 2.5 mg of medroxy- progesterone acetate failed to demonstrate cardiovascular protection. In fact, one showed a slight but significant increase in breast cancer and thrombotic disease after 5 years of continued use. Conjugated equine estrogens are one of the most utilized hormone products in Mexico and at the Instituto Mexicano del Seguro Social (IMSS) for pharmacologic treatment during climateric and postmenopause. For this reason, it is necessary to review the most recent scientific information concerning risks and benefits of the above-mentioned drug and hormonal replacement therapy also, with the purpose of updating management protocols in climateric and menopause and to aid the clinical practice of family physicians and gynecologists at the IMSS.


REFERENCES

  1. 1. Rosenbaum A, Wexler LE. Hormone repla-cement therapy: Does benefit out weight risk? Im Int Med 1994;15(12):23-28.

  2. 2. Campagnoli C, Lesca L, Cantamessa C, Peris C. Long-term hormone replacement treatment in menopause: new choices, old apprehensions, recent findings. Maturitas 1993;18(1):21-46.

  3. 3. Farish E, Rolton HA, Barnes JF, Fletcher CD, Walsh DJ, Spowart KJM, et al. Lipoprotein and postmenopausal oestrogen. Acta Endocrinol 1993;129(3):225-228.

  4. 4. Daly E, Roche M, Barlow D, Gray A, McPherson K, Vessey M. HRT: an analysis of benefits, risks and costs. Br Med Bull 1992;48(2):368-400.

  5. 5. Christiansen C. Prevention and treatment of osteoporosis with hormone replacement therapy. Int J Fertil 1993;38(Suppl 1):45-54.

  6. 6. Dallongeville J, Marecaux N, Isorez D, Zylberberg G, Fruchart JC, Amouyel P. Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women. Atherosclerosis 1995; 118(1):123-133.

  7. 7. Griewing B, Romer T, Ludemann J, Gunther A, Kessler C. Hormone replacement therapy in post-menopausal women: carotid intima media thickness and 3-D volumetric plaque quantification. Maturitas 1999;32(1):33-40.

  8. 8. Ottowitz WE III, Halbreich U. Mood and cognitive changes following estrogen replacement therapy in postmenopausal women. CNS Drugs 1995;4(3):161-167.

  9. 9. NIH Consensus Development Panel on Osteo-porosis, Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-793.

  10. Herrington DM, Rebousin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-529.

  11. Genant HK, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy. Effects on bone, plas-ma estradiol concentrations, endometrium and lipid levels. Arch Intern Med 1997;157:2609-2615.

  12. Brenner D, Kukull WA, Stergachis A, et al. Postme-nopausal estrogen replacement therapy and the risk of Alzheimer’s disease: a population-based case-control study. Am J Epidemiol 1994;140:262-267.

  13. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin form secondary preven-tion of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Repla-cement Study (HERS) Research Group. JAMA 1998;280:605-613.

  14. Speroff L. The Heart and Estrogen/Progestin Replacement Study (HERS). Maturitas 1998;31 (1):9-14.

  15. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women’s health initiative randomized controlled trial. JAMA 2002;288(3): 321-333.

  16. Velasco-Murillo V. Estrógenos equinos versus estrógenos esterificados en el climaterio y la meno-pausia. La controversia llega a México. Gac Med Mex 2001;137(3):237-243.

  17. Georgiev DB, Manassiev NA. Effect of long-term continuous combined hormone replacement therapy with estradiol valerate and either dienogest of norethisterone acetate on mammographic density in postmenopausal women. Medscape Women’s Health eJournal 7(4),2002. © 2002 Medscape.

  18. National Association of Nurse Practitioners in Women’s Health. Hormone replacement therapy: guidance from the National of Nurse Practitioners in Women’s Health. Topics in Advanced Practice Nursing eJournal 2(3), 2002. 2002 © Medscape.

  19. Bush T. Beyond HERS: some (not so) random thoughts on randomized clinical trials. Int J Fertil Womens Med 2001:46(2):55-59.

  20. Velasco-Murillo V, Pozos-Cavanzo JL, Cardona-Pérez JA. Terapia hormonal de reemplazo en el climaterio y la posmenopausia. Rev Med IMSS 2000;38(2):131-138.

  21. Modelska K, Cummings S. Tibolone for postmeno-pausal women: systematic review of randomized trials. J Clin End Metab 2002;87(1):16-23.




2020     |     www.medigraphic.com